Kura Oncology price target raised to $35 from $27 at Oppenheimer. Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $35 from $27, citing an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.